Business
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.\n Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update. Conference Call Details Date:Tuesday, November 10thTime:8:30 am Eastern TimeDomestic:877-300-8521International:412-317-6026Conference ID:10149733Webcast:http://public.viavid.com/index.php?id=142319 About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com. Investor Contacts: Will Brown Ashley R. RobinsonChief Financial Officer LifeSci Advisors, LLCPhone: 240-654-1450 [email protected] [email protected] Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 [email protected] \n\n\nSource: Altimmune, Inc.","length":5157,"tagName":"div"}]